학제간연구 | Interdisciplinary Studies in Gambling | 跨学科研究
- date : 2015-05-20 01:10|hit : 2072
-
- Article] Cost-effectiveness of highly active Antiretroviral therapy for HIV infection in Taiwan
-
DocNo of ILP: 4194
Doc. Type: Article
Title: Cost-effectiveness of highly active Antiretroviral therapy for HIV infection in Taiwan
Authors: Fang, CT; Chang, YY; Hsu, HM; Twu, SJ; Chen, KT; Chen, MY; Huang, LYL; Hwang, LS; Wang, JD
Full Name of Authors: Fang, Chi-Tai; Chang, Yu-Yin; Hsu, Hsu-Mei; Twu, Shiing-Jer; Chen, Kow-Tong; Chen, Mao-Yuan; Huang, Loreen Y. L.; Hwang, Ling-Shiang; Wang, Jung-Der
Keywords by Author: cost-effectiveness; HAART health policy; highly active antiretroviral therapy; HIV infection
Keywords Plus: QUALITY-OF-LIFE; FOLLOW-UP; HAART USE; SURVIVAL; TRANSMISSION; INDIVIDUALS; EXPECTANCY; POLICY; STATES; CARE
Abstract: Background/Purpose: Since the late 1980s, the Taiwanese government has provided all HIV-infected citizens with free access to antiretroviral therapy. Recently, there is controversy as to whether or not free access to expensive highly active antiretroviral therapy (HAART) should be continued for HIV-infected patients. This study aimed to evaluate the cost-effectiveness of HAART therapy. Methods: HAART-associated improvement in survival was obtained by analyzing the follow-up data of all HIV-positive patients identified during April 1984 to March 1997 (pre-HAART era) and May 1997 to April 2003 (HAART era) inTaiwan. Data on quality of life in HIV-positive patients was obtained from a crosssectional survey of 224 patients using standard gamble method and World Health Organization Quality of Life-BREF instrument. Information regarding the cost of HAART was obtained from the National Health insurance (NHI). Results: In 2000, the average annual NHI expenditure on HAART per HIV-positive patient receiving HAART was NT$210,018 (US$6177, at an exchange rate of 34.0 NT$/US$). In the AIDS group, the cost was NT$176,441 (US$5189) per life year gained and NT$241,700 (US$7109) per quality-adjusted life year gained. For non-AIDS patients, the corresponding costs were NT$226,156 (US$6652) and NT$332,582 (US$9782), respectively. These estimates have not yet included the additional cost savings from HAART-associated reduction in hospitalization and use of antimicrobial agents for opportunistic infections, and the additional life years gained from the reduction in HIV transmission under the universal availability of HAART. Conclusion: HAART for HIV infection is cost-effective, especially when the societal and epidemiologic factors are considered. We recommend that the policy of providing free HAART to all HIV-infected citizens be continued.
Cate of OECD: Clinical medicine
Year of Publication: 2007
Business Area: gamble
Detail Business: gamble
Country: Singapore
Study Area:
Name of Journal: JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
Language: English
Country of Authors: Natl Taiwan Univ, Coll Publ Hlth, Inst Occupat Med & Ind Hyg, Taipei 100, Taiwan; Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan; Natl Taiwan Univ Hosp, Dept Environm & Occupat Med, Taipei, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Publ Hlth, Taipei, Taiwan; Acad Sinica, Inst Stat Sci, Taipei 115, Taiwan
Press Adress: Wang, JD (reprint author), Natl Taiwan Univ, Coll Publ Hlth, Inst Occupat Med & Ind Hyg, 17 Hsu Chow Rd, Taipei 100, Taiwan.
Email Address: jdwang@ntu.edu.tw
Citaion:
Funding:
Lists of Citation: Badri M, 2006, PLOS MED, V3, P48, DOI 10.1371/journal.pmed.0030004; Bala MV, 1999, J CLIN EPIDEMIOL, V52, P1047, DOI 10.1016/S0895-4356(99)00074-8; BAYER R, 1986, JAMA-J AM MED ASSOC, V256, P1768, DOI 10.1001/jama.256.13.1768; Beck EJ, 2004, AIDS, V18, P2411; Bell CM, 2006, BRIT MED J, V332, P699, DOI 10.1136/bmj.38737.607558.80; Bernell SL, 2005, HEALTH POLICY, V71, P255, DOI 10.1016/j.healthpol.2004.08.012; Centers for Disease Control and Prevention, 2002, MMWR RECOMM REP, V51, P11; Chen YMA, 2007, LANCET, V369, P623, DOI 10.1016/S0140-6736(07)60291-8; Chen YMA, 2006, EMERG INFECT DIS, V12, P703; Evans Christopher, 2004, Health Care Manag Sci, V7, P43, DOI 10.1023/B:HCMS.0000005397.93173.bb; *DEP HHS, 2006, GUID US ANT AG HIV 1; Drummond MF, 2005, METHODS EC EVALUATIO; Efron B., 1993, INTRO BOOTSTRAP; Eichler HG, 2004, VALUE HEALTH, V7, P518, DOI 10.1111/j.1524-4733.2004.75003.x; Fang CT, 2007, QJM-INT J MED, V100, P97, DOI 10.1093/qjmed/hcl141; Fang CT, 2004, J INFECT DIS, V190, P879, DOI 10.1086/422601; Fang CT, 2002, QUAL LIFE RES, V11, P753, DOI 10.1023/A:1020870402019; Freedberg KA, 2001, NEW ENGL J MED, V344, P824, DOI 10.1056/NEJM200103153441108; Gebo KA, 2005, JAIDS-J ACQ IMM DEF, V40, P609, DOI 10.1097/01.qai.0000171727.55553.78; Halkitis PN, 2005, J HEALTH PSYCHOL, V10, P345, DOI 10.1177/1359105305051421; Ho JJ, 2006, SCAND J WORK ENV HEA, V32, P91; Ho WL, 2006, BONE MARROW TRANSPL, V37, P569, DOI 10.1038/sj.bmt.1705287; Hsieh GY, 2002, TAIWAN J PUBLIC HLTH, V21, P329; Hsiung PC, 2005, QUAL LIFE RES, V14, P141, DOI 10.1007/s11136-004-6252-z; Hwang JS, 1999, STAT MED, V18, P1627, DOI 10.1002/(SICI)1097-0258(19990715)18:13<1627::AID-SIM159>3.3.CO;2-4; Hwang JS, 2004, QUAL LIFE RES, V13, P1, DOI 10.1023/B:QURE.0000015299.45623.38; *INF DIS SOC TAIW, 2001, J MICROBIAL IMMUNOL, V34, P224; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; Lee ET, 1997, ANNU REV PUBL HEALTH, V18, P105, DOI 10.1146/annurev.publhealth.18.1.105; Liu CL, 2006, QUAL LIFE RES, V15, P941, DOI 10.1007/s11136-005-5913-x; McCormick AW, 2007, CLIN INFECT DIS, V44, P1115, DOI 10.1086/512816; MONTVALE NJ, 1998, MED EC; Owens DK, 1998, J GEN INTERN MED, V13, P716; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Parsons TD, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-11; Sendi PP, 1999, AIDS, V13, P1115, DOI 10.1097/00002030-199906180-00016; Teixeira PR, 2004, AIDS, V18, pS5, DOI 10.1097/01.aids.0000131318.67773.c7; WANG JD, 2002, BASIC PRINCIPLES PRA, P151; Warwick Z, 2006, INT J STD AIDS, V17, P479, DOI 10.1258/095646206777689189; [WHO WTO], 2002, WTO AGR PUBL HLTH JO; Wilson JE, 2003, ANN INTERN MED, V139, P157; 1990, LAW PREVENTION CONTR
Number of Citaion: 42
Publication: ELSEVIER SINGAPORE PTE LTD
City of Publication: SINGAPORE
Address of Publication: 3 KILLINEY ROAD 08-01, WINSLAND HOUSE 1, SINGAPORE, 239519, SINGAPORE
ISSN: 0929-6646
29-Character Source Abbreviation: J FORMOS MED ASSOC
ISO Source Abbreviation: J. Formos. Med. Assoc.
Volume: 106
Version: 8
Start of File: 631
End of File: 640
DOI: 10.1016/S0929-6646(08)60020-0
Number of Pages: 10
Web of Science Category: Medicine, General & Internal
Subject Category: General & Internal Medicine
Document Delivery Number: 206KU
Unique Article Identifier: WOS:000249183100005
- reply : 0
-
- list
-
- prev
- next